Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
|Articles|April 20, 2022
Daily Medication Pearl: Haloperidol (Haldol)
Author(s)Saro Arakelians, PharmD
Haloperidol (Haldol) is indicated for use in the treatment of schizophrenia and to control the symptoms of Tourette's disorder, as well as severe behavioral problems or hyperactivity in children.
Advertisement
Medication Pearl of the Day: Haloperidol (Haldol)
Indication: Haloperidol (Haldol) is indicated for use in the treatment of schizophrenia and is indicated to control the symptoms of Tourette's disorder. Haloperidol may also used to treat severe behavioral problems or hyperactivity in children unsuccessfully treated with psychotherapy or other medicines.
Insight:
- Dosing: The initial dose of haloperidol decanoate should not exceed 100 mg regardless of previous antipsychotic dose requirements– see package insert
- Dosage forms: 0.5 mg, 1 mg, 2 mg, 5 mg, 10 mg, 20 mg, 2 mg/ml, 5 mg/ml, 50 mg/ml.
- Adverse events: Neurologic symptoms, cardiovascular effects, leukopenia, neutropenia, and agranulocytosis.
- Mechanism of action: Mechanism of action is unknown. The active mechanism is to block postsynaptic dopamine receptors in the mesolimbic system of the brain.
- Manufacturer:Upsher-Smith Laboratories
Source:
Advertisement
Related to this article
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, whereas sulfonylureas signaled faster decline without it.
Authors of a pharmacist-directed transitions-of-care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
4
Tec-Dara Cuts Death Risk 78% Without Raising Fatal Toxicity
5